Trial Profile
A Phase 1/2 Study of SCH727965 in Patients With Malignant Melanoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Dinaciclib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
- 22 Jun 2016 Status changed from active, no longer recruiting to discontinued.
- 21 Feb 2013 Planned end date changed from 1 Aug 2010 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 21 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.